|
Bayer's Lynkuet™ (elinzanetant) approved in the U.S. for treatment of moderate to severe vasomotor symptoms due to menopause
|
28 October 2025 |
|
Bayer and Kumquat Biosciences enter global exclusive license and collaboration in precision oncology
|
13 August 2025 |
|
Vividion Therapeutics and Bayer further strengthen oncology development pipeline with clinical-stage WRN inhibitor
|
12 June 2025 |
|
Sevabertinib (BAY 2927088) granted FDA Priority Review for the treatment of patients with HER2-mutant non-small cell lung cancer
|
29 May 2025 |
|
BlueRock Therapeutics announces publication in Nature of 18-month data from Phase 1 clinical trial for bemdaneprocel, an investigational cell therapy for Parkinson's disease
|
23 April 2025 |
|
Bayer and Puhe BioPharma enter into global license agreement for clinical phase I PRMT5 inhibitor
|
27 March 2025 |
|
Bayer and Hurdle announce breakthrough in aging research
|
13 March 2025 |
|
AskBio Receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson's disease investigational gene therapy
|
19 February 2025 |
|
One of the largest global surveys of society's attitudes toward breakthrough technologies
|
23 January 2025 |
|
Bayer acquires HiDoc Technologies and Cara Care® app for irritable bowel syndrome
|
11 December 2024 |
|
Bayer Foundation announces Science Awards winners of 2024
|
06 November 2024 |
|
Bayer and Dewpoint Therapeutics sign licensing agreement for heart disease program
|
25 October 2024 |
|
Bayer submits EU marketing authorization application for elinzanetant to treat moderate to severe vasomotor symptoms
|
15 October 2024 |
|
BlueRock Therapeutics' investigational cell therapy bemdaneprocel for Parkinson's disease shows positive data at 24-months
|
30 September 2024 |
|
Bayer Co.Lab Shanghai opens as part of global expansion of life science incubator network
|
26 September 2024 |
|
Bayer and NextRNA Therapeutics enter strategic collaboration to develop small molecules targeting long non-coding RNAs (lncRNAs) in oncology
|
30 August 2024 |
|
Vividion Therapeutics to expand with new global research and development center
|
01 August 2024 |
|
Darolutamide meets primary endpoint in Phase III ARANOTE trial
|
17 July 2024 |
|
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson's disease
|
11 July 2024 |
|
Berlin Center for Gene and Cell Therapies kicked off in Berlin
|
25 June 2024 |